<DOC>
	<DOCNO>NCT01054300</DOCNO>
	<brief_summary>This Phase 1 pharmacokinetic , pharmacodynamic study understand manner body respond , well drug handle body , vs twice daily dose ertugliflozin ( PF-04971729 , MK-8835 ) participant type 2 diabetes .</brief_summary>
	<brief_title>Effects Of Ertugliflozin ( PF-04971729 , MK-8835 ) In Participants With Type 2 Diabetes ( MK-8835-040 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patients type 2 diabetes , 2 acceptable oral antidiabetes drug least 8weeks prior study . Patients type 1 diabetes , patient stroke , unstable angina , heart attack last 6months , uncontrolled blood pressure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>